The novel coronavirus disease 2019 (COVID-19) has grown to be a global public health emergency since patients were first detected in Wuhan, China. Thus far, no specific drugs or vaccines are available to cure the patients with COVID-19 infection. The immune system and inflammation are proposed to play a central role in COVID-19 pathogenesis. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. Intravenous infusion of MSCs has shown promising results in COVID-19 treatment. Here, we report a case of a severe COVID-19 patient treated with human umbilical cord Wharton’s jelly-derived MSCs (hWJCs) from a healthy donor in Liaocheng People’s Hospital, China, from February 24, 2020. The pulmonary function and symptoms of the patient with COVID-19 pneumonia was significantly improved in 2 days after hWJC transplantation, and recovered and discharged in 7 days after treatment. After treatment, the percentage and counts of lymphocyte subsets (CD3 + , CD4 + , and CD8 + T cell) were increased, and the level of IL-6, TNF-α, and C-reactive protein is significantly decreased after hWJC treatment. Thus, the intravenous transplantation of hWJCs was safe and effective for the treatment of patients with COVID-19 pneumonia, especially for the patients in a critically severe condition. This report highlights the potential of hWJC infusions as an effective treatment for COVID-19 pneumonia.
【저자키워드】 COVID-19, Treatment, immunomodulatory, Human umbilical cord Wharton’s jelly-derived MSCs, 【초록키워드】 Inflammation, Vaccine, severe COVID-19, Pneumonia, IL-6, Infection, C-reactive protein, MSCs, Symptom, drug, immune system, novel coronavirus disease, CD4, CD8, China, T cell, Pulmonary function, COVID-19 pathogenesis, Lymphocyte subset, Patient, mesenchymal stem cell, TNF-α, MSC, Safe, intravenous, intravenous infusion, global public health, CD3, effective, highlight, healthy donor, Wuhan, China, shown, significantly, the patient, treated, discharged, Liaocheng, patients with COVID-19, treatment for COVID-19, umbilical, Wharton’s jelly-derived MSC, with COVID-19, 【제목키워드】 Pneumonia, Potential treatment, stem cell, intravenous infusion, patients with COVID-19, umbilical,